Transitional discount drug cards offer stopgap until Medicare benefit kicks in

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.

This decision may lead to faster approval of new treatments for multiple myeloma.

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

Spending on the GLP-1 class of therapeutics is expected to grow by 378% to $8.1 billion by 2027.

The executive order was created to acknowledge the challenges faced by families in accessing affordable, high-quality care, mainly due to the gap between costs and what families can afford.